Literature DB >> 25973322

Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application.

Shuo Zhang1, Yong-Hua Yu2, Yong Zhang2, Wei Qu2, Jia Li2.   

Abstract

The role of radiotherapy (RT) in the management of urinary bladder cancer has undergone several alterations along the last decades. Recently, many protocols have been developed supporting the use of multi-modality therapy, and the concept of organ preservation began to be reconsidered. Advances in radiotherapy planning, verification, and delivery provide a method to optimize radiotherapy for bladder cancer and overcome difficulties which have previously limited the success of this treatment. They offer the opportunity to enhance the therapeutic ratio by reducing the volume of normal tissue irradiated and by increasing radiation dose or using more intensive fractionation and synchronous chemotherapy regimes. These techniques have a large potential to improve the therapeutic outcome of bladder cancer. In the near future, it should be possible to offer selected patients with muscle-invasive bladder cancer an organ-sparing, yet effective combined-modality treatment. In this review, we aim to present the role of radiotherapy in the management of muscle invasive bladder cancer. Alternative methods of improving treatment accuracy such as helical tomotherapy, adaptive radiotherapy and radiochemotherapy are also discussed.

Entities:  

Keywords:  ART; HT; Urinary bladder cancer; VMAT; radiotherapy

Year:  2015        PMID: 25973322      PMCID: PMC4396032     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  77 in total

1.  Improving bladder cancer treatment with radiotherapy using separate intensity modulated radiotherapy plans for boost and elective fields.

Authors:  D C van Rooijen; J B van de Kamer; M C C M Hulshof; C C E Koning; A Bel
Journal:  J Med Imaging Radiat Oncol       Date:  2010-06       Impact factor: 1.735

2.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

3.  Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).

Authors:  Jean-Léon Lagrange; Caroline Bascoul-Mollevi; Lionnel Geoffrois; Véronique Beckendorf; Jean-Marc Ferrero; Florence Joly; Nedjila Allouache; Jean-Marc Bachaud; Christine Chevreau; Andrew Kramar; Bruno Chauvet
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-10       Impact factor: 7.038

4.  Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors.

Authors:  C C E Koning; L E C M Blank; C Koedooder; R M van Os; M van de Kar; E Jansen; J J Battermann; M Beijert; C Gernaat; K A M van Herpen; C Hoekstra; S Horenblas; J J Jobsen; A D G Krol; M L M Lybeert; I E W van Onna; R C M Pelger; P Poortmans; F J Pos; E van der Steen-Banasik; A Slot; A Visser; B R Pieters
Journal:  Ann Oncol       Date:  2012-06-19       Impact factor: 32.976

5.  The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

Authors:  D S Kaufman; K A Winter; W U Shipley; N M Heney; M P Chetner; L Souhami; R A Zlotecki; W T Sause; L D True
Journal:  Oncologist       Date:  2000

6.  Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer.

Authors:  Vassilis Kouloulias; Maria Tolia; Nikolaos Kolliarakis; Argyris Siatelis; Nikolaos Kelekis
Journal:  Int Braz J Urol       Date:  2013 Jan-Feb       Impact factor: 1.541

Review 7.  Radiation-induced second cancers: the impact of 3D-CRT and IMRT.

Authors:  Eric J Hall; Cheng-Shie Wuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

8.  Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution.

Authors:  Yi-Jen Chen; An Liu; Chunhui Han; Peter T Tsai; Timothy E Schultheiss; Richard D Pezner; Nilesh Vora; Dean Lim; Stephen Shibata; Kemp H Kernstine; Jeffrey Y C Wong
Journal:  Med Dosim       Date:  2007       Impact factor: 1.482

9.  A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy.

Authors:  John C Roeske; Dacian Bonta; Loren K Mell; Anthony E Lujan; Arno J Mundt
Journal:  Radiother Oncol       Date:  2003-11       Impact factor: 6.280

10.  A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer.

Authors:  Farshad Foroudi; Lesley Wilson; Mathias Bressel; Annette Haworth; Colin Hornby; Daniel Pham; Jim Cramb; Suki Gill; Keen Hun Tai; Tomas Kron
Journal:  Radiat Oncol       Date:  2012-07-23       Impact factor: 3.481

View more
  10 in total

1.  Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Skóra; Bogumiła Szyszka-Charewicz; Jerzy Jakubowicz
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

2.  Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer.

Authors:  Victor A McPherson; George Rodrigues; Glenn Bauman; Eric Winquist; Joseph Chin; Jonathan Izawa; Kylea Potvin; Scott Ernst; Varagur Venkatesan; Tracy Sexton; Belal Ahmad; Nicholas Power
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

3.  Induction of Mitotic Catastrophe via Inhibition of Aurora B by Ionizing Radiation With Additive of Mulberry Water Extract in Human Bladder Cancer Cells.

Authors:  Chia-Cheng Su; Nien-Cheng Chen; Charng-Cherng Chyau; Hsien-Chun Tseng; Fen-Pi Chou
Journal:  Integr Cancer Ther       Date:  2018-11-15       Impact factor: 3.279

4.  PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target.

Authors:  Holger Hans Hermann Erb; Marlies Ebert; Ronja Kuhn; Lukas Donix; Axel Haferkamp; Robert Ian Seed; Eva Jüngel
Journal:  PLoS One       Date:  2019-10-22       Impact factor: 3.240

5.  An ultrasound based platform for image-guided radiotherapy in canine bladder cancer patients.

Authors:  Justin T Sick; Nicholas J Rancilio; Caroline V Fulkerson; Jeannie M Plantenga; Deborah W Knapp; Keith M Stantz
Journal:  Phys Imaging Radiat Oncol       Date:  2019-11-15

6.  Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience.

Authors:  Chinmayee Agrawal; Saurabh Bansal; Manoj Biswas; Meenu Gupta; Vipul Nautiyal; Mushtaq Ahmed
Journal:  South Asian J Cancer       Date:  2021-04-26

7.  A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.

Authors:  Ben-Max de Ruiter; Maaike W van de Kamp; Jonah P Z van Steenbergen; Martine Franckena; Joost L Boormans; Jeantine M de Feijter; Adriaan D Bins; Maarten C C M Hulshof; Theo M de Reijke; Eva Schaake; Jorg R Oddens
Journal:  Eur Urol Open Sci       Date:  2022-03-16

Review 8.  Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments.

Authors:  Giandomenico Roviello; Martina Catalano; Raffaella Santi; Matteo Santoni; Ilaria Camilla Galli; Andrea Amorosi; Wojciech Polom; Ugo De Giorgi; Gabriella Nesi
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

Review 9.  Nanotechnology in Bladder Cancer: Diagnosis and Treatment.

Authors:  Mahmood Barani; Seyedeh Maryam Hosseinikhah; Abbas Rahdar; Leila Farhoudi; Rabia Arshad; Magali Cucchiarini; Sadanand Pandey
Journal:  Cancers (Basel)       Date:  2021-05-05       Impact factor: 6.639

10.  Correlation between gastric volume and organs at risk dose in adjuvant radiotherapy for left breast cancer.

Authors:  Zahra Siavashpour; Mona Malekzadeh Moghani; Neda Goharpey; Hamid Reza Mirzai; Leila Kia Mohammadi; Farid Zayeri
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.